ALK-Abelló Valuation

Is ALK B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALK B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
DKK 213.29
Fair Value
32.4% undervalued intrinsic discount
4
Number of Analysts

Below Fair Value: ALK B (DKK144.1) is trading below our estimate of fair value (DKK213.29)

Significantly Below Fair Value: ALK B is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALK B?

Key metric: As ALK B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ALK B. This is calculated by dividing ALK B's market cap by their current earnings.
What is ALK B's PE Ratio?
PE Ratio39.1x
EarningsDKK 815.00m
Market CapDKK 32.87b

Price to Earnings Ratio vs Peers

How does ALK B's PE Ratio compare to its peers?

The above table shows the PE ratio for ALK B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.3x
HLUN B H. Lundbeck
8.7x6.3%DKK 26.5b
NOVO B Novo Nordisk
17.1x13.3%DKK 1.9t
GMAB Genmab
10.4x13.6%DKK 80.8b
CHEMM ChemoMetec
49.1x17.7%DKK 8.3b
ALK B ALK-Abelló
39.1x15.5%DKK 31.9b

Price-To-Earnings vs Peers: ALK B is expensive based on its Price-To-Earnings Ratio (39.1x) compared to the peer average (21.3x).


Price to Earnings Ratio vs Industry

How does ALK B's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
ALK B 39.1xIndustry Avg. 20.9xNo. of Companies8PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ALK B is expensive based on its Price-To-Earnings Ratio (39.1x) compared to the European Pharmaceuticals industry average (20.9x).


Price to Earnings Ratio vs Fair Ratio

What is ALK B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALK B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio39.1x
Fair PE Ratio19.5x

Price-To-Earnings vs Fair Ratio: ALK B is expensive based on its Price-To-Earnings Ratio (39.1x) compared to the estimated Fair Price-To-Earnings Ratio (19.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALK B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 144.10
DKK 181.25
+25.8%
3.7%DKK 190.00DKK 173.00n/a4
Apr ’26DKK 141.00
DKK 181.25
+28.5%
3.7%DKK 190.00DKK 173.00n/a4
Mar ’26DKK 153.10
DKK 181.25
+18.4%
3.7%DKK 190.00DKK 173.00n/a4
Feb ’26DKK 162.80
DKK 180.75
+11.0%
3.9%DKK 190.00DKK 173.00n/a4
Jan ’26DKK 159.10
DKK 172.75
+8.6%
7.6%DKK 190.00DKK 153.00n/a4
Dec ’25DKK 162.00
DKK 181.20
+11.9%
11.4%DKK 215.00DKK 153.00n/a5
Nov ’25DKK 163.60
DKK 177.00
+8.2%
9.3%DKK 200.00DKK 153.00n/a5
Oct ’25DKK 171.10
DKK 177.00
+3.4%
9.3%DKK 200.00DKK 153.00n/a5
Sep ’25DKK 179.00
DKK 168.60
-5.8%
15.3%DKK 200.00DKK 128.00n/a5
Aug ’25DKK 156.50
DKK 155.40
-0.7%
11.5%DKK 180.00DKK 128.00n/a5
Jul ’25DKK 151.10
DKK 155.40
+2.8%
11.5%DKK 180.00DKK 128.00n/a5
Jun ’25DKK 152.60
DKK 155.00
+1.6%
11.4%DKK 175.00DKK 126.00n/a5
May ’25DKK 131.20
DKK 132.75
+1.2%
7.6%DKK 145.00DKK 120.00n/a4
Apr ’25DKK 124.10
DKK 125.00
+0.7%
15.0%DKK 140.00DKK 94.00DKK 141.004
Mar ’25DKK 130.40
DKK 120.75
-7.4%
16.5%DKK 140.00DKK 94.00DKK 153.104
Feb ’25DKK 110.70
DKK 112.00
+1.2%
10.6%DKK 125.00DKK 94.00DKK 162.804
Jan ’25DKK 101.20
DKK 110.75
+9.4%
9.6%DKK 120.00DKK 94.00DKK 159.104
Dec ’24DKK 91.75
DKK 110.75
+20.7%
9.6%DKK 120.00DKK 94.00DKK 162.004
Nov ’24DKK 76.45
DKK 117.80
+54.1%
21.3%DKK 160.00DKK 89.00DKK 163.605
Oct ’24DKK 79.45
DKK 112.80
+42.0%
25.2%DKK 160.00DKK 85.00DKK 171.105
Sep ’24DKK 83.10
DKK 116.40
+40.1%
22.5%DKK 160.00DKK 85.00DKK 179.005
Aug ’24DKK 74.15
DKK 128.20
+72.9%
23.6%DKK 169.00DKK 95.00DKK 156.505
Jul ’24DKK 74.45
DKK 128.20
+72.2%
23.6%DKK 169.00DKK 95.00DKK 151.105
Jun ’24DKK 82.15
DKK 124.20
+51.2%
27.0%DKK 169.00DKK 90.00DKK 152.605
May ’24DKK 86.50
DKK 129.20
+49.4%
22.6%DKK 169.00DKK 100.00DKK 131.205
Apr ’24DKK 106.10
DKK 141.20
+33.1%
15.6%DKK 169.00DKK 107.00DKK 124.105
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
DKK 181.25
Fair Value
20.5% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/22 18:18
End of Day Share Price 2025/04/22 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ALK-Abelló A/S is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Alexandru CogutBryan Garnier & Co
Jesper IlsoeCarnegie Investment Bank AB